

# TREATING INFECTED DIABETIC WOUNDS WITH SUPEROXIDIZED WATER AS ANTI-SEPTIC AGENT : A PRELIMINARY EXPERIENCE

Syed Fazle Hadi, Tanwir Khaliq\*, Nighat Bilal, Imran Sikandar\*\*, Muhammad Saaq\*, Muhammad Zubair\* and Sidra Aurangzeb

## ABSTRACT

**Objective:** To evaluate the effectiveness of superoxidized water (Microcyn™) in diabetic patients with different wounds.

**Study Design:** Single-centre single blinded randomized controlled trial.

**Place and Duration of Study:** Department of General Surgery, Orthopaedics and General Medicine at Pakistan Institute of Medical Sciences, Islamabad, from April to June 2006.

**Patients and Methods:** One hundred known diabetic patients were enrolled. Half were randomized to the intervention group (those whose wounds were managed with superoxidized water) and half to the control group (whose wounds were treated with normal saline) using a table of random numbers. The two groups were matched for age, gender, duration of diabetes and category of wound. All patients received appropriate surgical treatment for their wounds as required. Local wound treatment was carried out daily using superoxidized water soaked gauzes on twice daily basis in the intervention group and normal saline in the control group. The treatment was continued until wound healing. The main outcome measures were duration of hospital stay, downgrading of the wound category, wound healing time and need for interventions such as amputation.

**Results:** Statistically significant differences were found in favour of the superoxidized water group with respect to duration of hospital stay, downgrading of the wound category and wound healing time.

**Conclusion:** Although the initial results of employing superoxidized water for the management of infected diabetic wounds are encouraging, further multicentre clinical trials are warranted before this antiseptic is recommended for general use. It may offer an economical alternative to other expensive antiseptics with positive impact on the prevailing infection rates, patient outcomes and patient satisfaction.

**KEY WORDS:** *Wound infection. Diabetic wounds. Antiseptic agents. Superoxidized water.*

---

## INTRODUCTION

Diabetic foot is one of the most serious complications of diabetic wounds and is the leading cause of non-traumatic lower limb amputations.<sup>1</sup> If a standardized treatment approach is applied with a multidisciplinary foot care team, major amputations can be avoided in about 80-90% of patients with limb threatening ischemia and in 95% of patients with infection.<sup>2</sup>

Over the years, a variety of strategies have been evolved to address the issue of wound infection. One of such strategies is the use of superoxidized solutions. Most of these solutions or waters are electrochemically processed aqueous solutions manufactured from pure water and sodium chloride. In general, the concept of electrolysis is relatively simple: tap water is purified through reverse-osmosis and USP-grade sodium chloride is added before being submitted to an electric field. During the process of electrolysis, molecules are pulled apart in a chamber with positive and negative poles and hypochlorite/ous species and free radicals are formed. The

final result is a blend of reactive species of chloride and oxygen with its numerous applications in medicine and disinfection. Superoxidized water (Microcyn™) is a pH-neutral, superoxidized solution with a longer shelf-life (> 12 months) than any other superoxidized solution tested to-date.<sup>3</sup> It has proved its antimicrobial activity against a variety of microbes including bacteria, viruses, fungi and bacterial spores. It has been effective and safe when applied in different ways (e.g. sprays, immersion, irrigation, etc.) as well as in combination with other technologies. It can be applied 2-3 times daily according to the type and stage of the wound.<sup>3-4</sup>

The aims of this study was to evaluate the effectiveness of superoxidized water in diabetic patients with different wounds.

## PATIENTS AND METHODS

Between April 15, 2006 and June 14, 2006, this pilot clinical study (single-centre single blinded randomized controlled trial) was undertaken at the Departments of General Surgery, Orthopaedics and General Medicine. One hundred known diabetic patients were enrolled in the study. Informed consent for participation in the study was taken from all the study subjects to be randomized to either intervention or control

Department of General Medicine, P.I.M.S., Islamabad.

\*Department of General Surgery, P.I.M.S., Islamabad.

\*\*Department of Orthopaedics, P.I.M.S., Islamabad.

**Correspondence:** Dr. Syed Fazle Hadi, Executive Director, Pakistan Institute of Medical Sciences (PIMS), Islamabad.

Received September 14, 2006; accepted June 26, 2007.

group without being aware of it. The Research and Ethics Committee of the hospital approved the study. Half of the subjects were randomized to the intervention group (those whose wounds were managed with superoxidized water) and half to the control group (whose wounds were treated with normal saline). A table of random numbers was employed to achieve simple random samples. The two groups were matched for age, gender, duration of diabetes and category of wound.

All patients received appropriate surgical treatment for their wounds e.g. incision/drainage for abscess and carbuncle, debridement for infected wounds, amputation for osteomyelitis. Additionally, all patients received intravenous Ofloxacin 200 mg b.i.d until wound healing. Local wound treatment was carried out daily using superoxidized water soaked gauzes on twice daily basis in the intervention group while employing normal saline in the control group. About 5-10 cc of superoxidized water was used for each dressing depending on the size of the wound. The treatment was continued till the wound healing.

Wounds were categorized by allocating grades to various stages of wounds and a shift from higher to lower grade with treatment was considered as downgrading. Wounds with necrotic tissue or frank pus were considered as of Grade IV, wounds with slight slough or serosanguinous discharge were taken as of Grade III, wounds with appearance of healthy granulation tissue were taken as of Grade II and wounds with healthy epithelialization were taken as of Grade I.

The main outcome measures included duration of hospital stay, downgrading of the wound category, wound healing time and need for additional interventions such as amputation.

The data were analyzed through SPSS for Windows version 10 and various descriptive statistics were used to calculate frequencies, ratios, percentages, means and standard deviation. The nominal variables were reported as frequency and percentages. The numerical data were reported as mean ± standard deviation. The difference between two means was regarded as statistically significant if p-value was less than 0.05.

## RESULTS

Each group included 50 patients of either gender. The male to female ratio was 43:7 respectively. The average age of the patients was 40 ± 11 years. Most of the wounds were infected diabetic foot ulcers (n = 29), while infected operative wounds were 09, carbuncles 07, and gangrenous wounds were 05. Areawise, the wounds were located on foot (n=31), abdomen (n=9), back (n=7) and upper limb (n=3). At presentation, the majority of wounds were of grade IV ( n=34), while grade III wounds were 10 and grade II wounds were 6 in each group. The Table I shows the wound downgrading observed after one week of treatment in the two groups. The duration of hospitalization among the patients of the two groups is depicted in Table II.

Statistically significant differences were apparent in favour of the intervention group with respect to the duration of hospital stay, downgrading of the wound category and wound healing time. Owing to the relatively small number of study subjects, the difference of amputations between the two

**Table I:** Wound downgrading observed with one week of treatment (n= 50 each group ).

S. No.	Wound category on day 01	Wound category on day 08	No. of patients (study group)	No. of patients (control group)	p-value (%)
1	IV	I	21 (61.76%)	5 (14.7%)	p < 0.05
2	IV	II	8 (23.52%)	13 (38.23%)	p > 0.05
3	IV	III	5 (14.7%)	16 (47%)	p < 0.05
4	III	I	7 (70%)	2 (20%)	p < 0.05
5	III	II	3 (30%)	8 (80%)	p < 0.05
6	II	I	6 (100%)	3 (50%)	p < 0.05

**Table II:** The duration of hospitalization among the patients of the two groups (n = 50 each group).

S. No.	Duration of hospitalization	No. of patients (study group)	No. of patients (control group)	p-value (%)
1	1-7 DAYS	31 (62%)	10 (20%)	p < 0.05
2	8-14 DAYS	9 (18%)	17 (34%)	p < 0.05
3	15-21 DAYS	7 (14%)	15 (30%)	p < 0.05
4	>21 DAYS	3 (6%)	8 (16%)	p > 0.05

groups remained statistically insignificant.

## DISCUSSION

These preliminary results are promising indicating feasibility and operational efficiency of the new antiseptic agent in the management of diabetic wounds. The objective of presenting this initial data set was to prompt other local investigators to carry out similar studies, and hence, allow more meaningful comparison of results in the local population.

Most of the data regarding factors related to the outcome of diabetic foot ulcers are based on cross-sectional and often retrospective studies with differing patients' selection criteria, definitions and management protocols. Owing to the lack of standardization and uniformity, the results are usually unreliable and inconclusive. Thus, the study was prospective and took a multitude of factors into consideration with disregard to the glycemic levels, age, gender and duration of diabetes. Only a group of surgeons and physicians was involved in treating the patients with the antiseptic agent under trial. Hence, this study was more uniform and well- controlled. Moreover, the study subjects were blinded to the therapy employed.

Diabetes is a serious chronic illness with various hereditary and environmental factors contributing to its aetiopathogenesis. Though it has several serious complications with devastating socioeconomic implications, foot complications and skin infections take the heavy toll. A complexity of factors determine the outcome of foot ulcers in diabetics. Healing rates of foot ulcers are not exactly known except in the world's best centres where they are in the range of 80-90 %.<sup>1-4</sup>

Aerobic gram-positive cocci are the predominant pathogens in diabetic foot infections, however, polymicrobial infections predominate in severe diabetic foot infection and include a variety of aerobic gram-positive cocci, gram-negative rods and anaerobes. In the past, debridement, meticulous wound care and antibiotics constituted the cornerstones of management, however, with the increasing emergence of MRSA and other resistant bacterial strains, the need for novel approaches to diabetic wounds was felt.<sup>5-7</sup> The use of antiseptic agents

including superoxidized water is one of such innovative approaches.<sup>3-4</sup>

Superoxidized water is a relatively newer antiseptic agent and these initial results prove its superiority over normal saline in treating a broad spectrum of diabetic wound infections. The antiseptics can be employed to prevent and treat infection while preserving the healing process. They are preferable to topical antibiotics with regard to the development of bacterial resistance.<sup>8-10</sup> Several studies have proved that antiseptic solutions are more effective than just saline alone when used as a wound cleanser to promote wound healing.<sup>11-13</sup> Superoxidized solutions are well-validated disinfectants for various instruments and hard inanimate surfaces in hospitals.<sup>14-17</sup> These solutions have also been used with success on humans for a variety of indications such as treatment of infectious skin defects, ulcers, mediastinal irrigation after open-heart surgery, treatment of peritonitis, intra-peritoneal abscess and hand washing etc.<sup>18-22</sup> Superoxidized water has been enjoying worldwide approval and large-scale recognition in the recent years and our initial results are in conformity with the other reported studies.<sup>3,4</sup>

Superoxidized water, owing to its low cost, can provide an economical alternative to the other available antiseptic agents. The economic implications of diabetic wound infections are devastating, particularly in poor societies. In the United States, over 5 million patients suffer from different chronic wounds annually at a total cost of greater than 20 billion US dollars a year.<sup>23-24</sup> The yearly cost of treating pressure ulcers alone are greater than one billion US dollars and 1.5-3 million US adults require treatment in long-term care settings.<sup>25</sup> In the US, the national daily hospital cost of Medicare patient averages 2,360 dollars and the overall yearly cost of infections worldwide are estimated to be greater than 100 billion US dollars. Diabetic wounds constitute a significant percentage of these. Any strategy aimed at rapidly sterilizing the wounds, decrease intravenous and oral antibiotics use, decrease hospitalization, and facilitate time to wound healing and have a significant clinical and economical impact.<sup>26</sup> Such an impact would be a great welcome for nations of the developing world.

These are the results of our preliminary study and the ongoing study still continues, its detailed results would be submitted for publication as soon as the study is completed.

## CONCLUSION

Although the initial results of employing Super-oxidized water for the management of infected diabetic wounds are encouraging, further multicentre clinical trials are warranted before this antiseptic is recommended for general use in our population. Moreover, it must offer an economical alternative to other expensive antiseptics with positive impact on the prevailing infection rates, patient outcomes and patient satisfaction.

**ACKNOWLEDGEMENT:** We are thankful to M/s. Oculus Innovative Sciences, Inc. for their free-of-cost and liberal provision of superoxidized water (Microcyn™) for the study subjects.

## REFERENCES

1. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. *Am Fam Physician* 1998; **57**:1325-32, 1337-8.
2. Holstein P, Ellitsgaard N, Oslen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. *Diabetologia* 2000; **43**: 844-7.
3. Martinez-Munive A, Menedez-Skertchly A, Toiber M. Superoxidized water (Microcyn 60 ) for mesh hernioplasty in grossly contaminated fields: an experimental study. SE 163. Presented at the American-College of Surgeons, 91<sup>st</sup> Annual Congress in San Francisco, California. 2005 : p.16-20.
4. Paola D, Brocco E, Senesi A. Use of Dermacyn: a new antiseptic agent for local treatment of diabetic foot ulcers. *J Wound Healing* 2005; **2**: 201.
5. Lipsky BA. Infectious problems of the foot in diabetic patients. In : Bowker JH, Pfeifer MA, (edi). Levin and O'Neil's the diabetic foot. 6<sup>th</sup> ed. Mosby 2001.
6. American Diabetes Association. Consensus development conference on diabetic foot wound care. Boston: Massachusetts: *Diabetes Care*;1999; **22**:1354-60.
7. Caballero E, Frykberg RG. Diabetic foot infections. *J Foot Ankle Surg* 1998; **37**: 248-55.
8. Bergstrom N, Bennet MA, Carlson CE. Clinical practice guideline number 15 : treatment of pressure ulcers. Rockville MD. US Department of Health and Human Services. Agency for health care policy and research. AHCPR Pub1994; **65**-652.
9. International Working Group on the diabetic foot international consensus on the diabetic foot. Amsterdam: The Group; 1999.
10. Lindfors J. A comparison of an antimicrobial wound cleanser to normal saline in reduction of bioburden and its effect on wound healing. *Ostomy Wound Manage* 2004; **50**: 28-41.
11. Konya C, Sanada H, Sugama J, Okuwa M, Kitagawa A. Does the use of a cleanser on skin surrounding pressure ulcers in older people promote healing ? *J Wound Care* 2005;**14**:169-71.
12. Motta GJ, Milne CT, Corbett LQ. Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. *Ostomy Wound Manage* 2004; **50**: 48-62.
13. Park H, Hung YC, Kim C. Effectiveness of electrolyzed water as a sanitizer for treating different surfaces. *J Food Prot* 2002; **65**:1276-80.
14. Rutala WA, Weber DJ. New disinfection and sterilization methods. *Emerg Infect Dis* 2001; **7**: 348-53.
15. Tanaka N, Tanaka N, Fujisawa T, Daimon T, Fujiwara K, Yamamoto M, et al. The use of electrolyzed solutions for the cleaning and disinfecting of dialyzers. *Artif Organs* 2000; **24**: 921-8.
16. Nelson D. Newer technologies for endoscope disinfection: electrolyzed acid water and disposable-component endoscope systems. *Gastrointest Endosc Clin N Am* 2000; **10**: 319-28.
17. Sekiya S, Ohmori K, Harii K. Treatment of infectious skin defects or ulcers with electrolyzed strong acid aqueous solution. *Artif Organs* 1997; **21**:32-8.
18. Ohno H, Higashidate M, Yokosuka T. Mediastinal irrigation with superoxidized water after open-heart surgery : the safety and pitfalls of cardiovascular surgical application. *Surg Today* 2000; **30**:1055-6.
19. Inoue Y, Endo S, Kondo K. Trial of electrolyzed strong acid aqueous solution lavage in the treatment of peritonitis and intra-peritoneal abscess. *Artif Organs* 1997;**21**:28-31.
20. Sakashita M, Iwasawa A, Nakamura Y. Anti-microbial effects and efficacy on habitually hand-washing of strong acidic electrolyzed water a comparative study of alcoholic anti-septics and soap and tap water. *Kansenshogaku Zasshi* 2002; **76**: 373-7.
21. Tanaka H, Hirakata Y, Kaku M, Yoshida R, Takemura H, Mizukane R, et.al. Antimicrobial activity of superoxidized water. *J Hosp Infect* 1996; **34**:43-9.

22. Landa-Solis C, Gozalez-Espinosa D, Guzman-Soriano B, Snyder M, Reyes-Teran G, Tarres K, et.al. Microcyn a novel superoxidized water with neutral pH and disinfectant activity. *J Hosp Infect* 2005; **61**: 291-9.
23. Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ. Improved survival of the diabetic foot: the role of a specialized foot clinic. *Q J Med* 1986; **60**:763-71.
24. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant *Staphylococcus aureus* in diabetic foot clinic: a worsening problem. *Diabet Med* 2003;**20**:159-61.
25. Wanger A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant *Staphylococcus aureus* infections. *Dtsch Med Wochenschr* 2001; **126**:1353-6.
26. Drosou A, Falabella A, Kirsner S. Antiseptics on wounds : an area of controversy. *Wounds* 2003;**15**:149-66.

